Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-025-04848-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Lina Eltaib und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit nennt 219 Literaturangaben. Gefördert von: Deanship of Scientific Research at Northern Border University.
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) are a potential category of specialized cancer therapeutics that integrate monoclonal antibodies (mAbs) with cytotoxic drugs. These therapies seek to provide very effective pharmaceuticals directly to neoplastic cells, enhancing the therapeutic index compared to traditional chemotherapy. Despite their clinical success, ADCs face significant challenges, particularly in the form of resistance mechanisms that limit their effectiveness. Resistance can arise through various pathways, including antigen-related alterations, impaired drug internalization, and inefficient payload release. Other factors that complicate ADC penetration and efficacy are tumor microenvironment factors, including hypoxia and acidic pH. This review discusses the mechanistic origin of ADC resistance, and investigates the major biological, chemical, and pharmacokinetic variables related to treatment failure. We also indicate the new approaches to fighting resistance, such as next-generation ADCs designs, drug combination therapies, and tumor microenvironment modulation. Lastly, we talk about the possibility of new payloads, better linkers, and other possible drug delivery systems that could further the ADC efficacy to combat cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia.
- Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah, 21442, Saudi Arabia.
- Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park 2, Greater, Noida, India.
- Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of Biotechnology, Graphic Era (Deemed to be University), Clement Town, Dehradun, 248002, India.
- Centre for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College, Saveetha University, Chennai, India.
Förderung
- Deanship of Scientific Research at Northern Border University
Zitieren
APA
Eltaib, L., Afzal, M., Maji, C., Malathi, H., Goyal, K., Ali, H., Gupta, G., & Hussain, M. S. (2025). Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04848-8
Vancouver
Eltaib L, Afzal M, Maji C, Malathi H, Goyal K, Ali H, et al. Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04848-8
BibTeX
@article{Eltaib2025,
author = {Eltaib, Lina and Afzal, Muhammad and Maji, Chandana and Malathi, H and Goyal, Kavita and Ali, Haider and Gupta, Gaurav and Hussain, Md Sadique},
title = {Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-025-04848-8}
}
EUVIMED